about
Predictive models, based on classification algorithms, for compounds potentially active as mitochondrial ATP-sensitive potassium channel openers.Nutraceutical Value of Citrus Flavanones and Their Implications in Cardiovascular Disease.Arylthioamides as H2S Donors: l-Cysteine-Activated Releasing Properties and Vascular Effects in Vitro and in VivoDrug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics.(+/-)-Naringenin as large conductance Ca(2+)-activated K+ (BKCa) channel opener in vascular smooth muscle cellsThe Citrus Flavanone Naringenin Protects Myocardial Cells against Age-Associated Damage.Hydrogen sulphide: novel opportunity for drug discovery.Mitochondrial potassium channels as pharmacological target for cardioprotective drugs.Inhibitors of the renal outer medullary potassium channel: a patent review.Flavonoids and mitochondrial pharmacology: A new paradigm for cardioprotection.Using hydrogen sulfide to design and develop drugs.The Citrus Flavanone Naringenin Produces Cardioprotective Effects in Hearts from 1 Year Old Rat, through Activation of mitoBK Channels.Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors.Vasorelaxation by hydrogen sulphide involves activation of Kv7 potassium channels.Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties.Synthesis and biological evaluation of 5-membered spiro heterocycle-benzopyran derivatives against myocardial ischemia.Synthesis of heterocycle-based analogs of resveratrol and their antitumor and vasorelaxing properties.Anti-ischemic properties of a new spiro-cyclic benzopyran activator of the cardiac mito-KATP channel.Iminothioethers as Hydrogen Sulfide Donors: From the Gasotransmitter Release to the Vascular Effects.Anti-ischaemic activity of an antioxidant aldose reductase inhibitor on diabetic and non-diabetic rat hearts.Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors.Synthesis and evaluation of antihypertensive activity of 1,8-naphthyridine derivatives. Part X.Cardioprotective effects of different flavonoids against myocardial ischaemia/reperfusion injury in Langendorff-perfused rat hearts.Vasodilator activity of crude methanolic extract of Gentiana kokiana Perr. et Song. (Gentianaceae).Cardiovascular effects of Urtica dioica L. (Urticaceae) roots extracts: in vitro and in vivo pharmacological studies.R+-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors.Highly potent 1,4-benzothiazine derivatives as K(ATP)-channel openers.Effects of cannabinoids on non-adrenergic non-cholinergic-mediated relaxation in guinea-pig trachea.The xanthones gentiacaulein and gentiakochianin are responsible for the vasodilator action of the roots of Gentiana kochiana.Synthesis and beta-blocking activity of (R,S)-(E)-oximeethers of 2,3-dihydro-1,8-naphthyridine and 2,3-dihydrothiopyrano[2,3-b]pyridine: identification of beta 3-antagonists.Mitochondriotropic and Cardioprotective Effects of Triphenylphosphonium-Conjugated Derivatives of the Diterpenoid Isosteviol.Vasodilator activity of Michelia figo Spreng. (Magnoliaceae) by in vitro functional study.QT prolongation in anaesthetized guinea-pigs: an experimental approach for preliminary screening of torsadogenicity of drugs and drug candidates.NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same?The activation of mitochondrial BK potassium channels contributes to the protective effects of naringenin against myocardial ischemia/reperfusion injury.Vasorelaxing effects of flavonoids: investigation on the possible involvement of potassium channels.Vasorelaxant effects of the chloroformic crude extract of Bupleurum fruticosum L. (Umbelliferae) roots on rat thoracic aorta.NO-glibenclamide derivatives: prototypes of a new class of nitric oxide-releasing anti-diabetic drugs.The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endSpirocyclic benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel.
P50
Q33481422-BCF31560-470B-4853-BB62-F9FE5C028A43Q33749525-17A93A62-ABDF-40A3-986F-F69ED9B27E28Q35181925-BBE9827F-82DA-4057-BB77-8C6DC7B82690Q36048792-54070C86-B1AA-43A6-8AAD-2A8CC347EC7DQ36054330-62C01452-AA1D-4085-B937-EFF34600930AQ37721081-7985D13F-9135-4677-A30C-22AC337B19A4Q38051531-3E4D9394-03DF-4140-A7EE-4877A25AA294Q38262884-535133BD-082C-4B11-810E-D97038B02D3DQ38500527-4D4A1163-47F5-42C1-AD3F-1E58227ACA0FQ38501301-997F8B44-4BC3-4E0E-B63C-4EC9EE7CAAEBQ38643114-A0DA01D0-0134-47B1-A1BE-2C2FA21EDD94Q38910312-4199A730-7EFC-4958-8050-E7E47D6E2394Q39039040-4A36B396-85BF-4311-9B14-F9FAC5ADD40BQ39216830-12009287-153C-4239-ACFC-6BCE26EFF7D6Q39459414-C8164A2D-C4B8-48DD-8570-CEAD3E1142E5Q39599014-61168366-F7B1-43C3-B86E-8F8BEC278B11Q39664910-2F2F2DF7-E9FE-488A-A289-25A97A423060Q39816030-7E73B9EC-9858-4F01-9D0E-63616BAD86A0Q42513564-AA507CE5-0AFA-49A5-BEE3-653535FBCAD8Q42932522-A60ECF7E-27F2-4A61-B593-BEC7BFDDAB09Q43583233-A65AFDA5-A096-4284-9021-9429B5FEA75BQ43832562-991F9273-D7F7-4F51-BE33-9304431C1A9CQ43849364-76EEC042-7059-435E-9FE0-EEA6C35AAEBFQ43890095-54842970-9351-463C-A649-0029B4A7BBDEQ44000396-D09C8C3A-C23B-483A-B0D3-CEEB7C6B8F6AQ44264992-3615A601-70BE-4D2F-BA11-832C86D25E58Q44540235-8541D70E-B8D1-4766-95D0-CD21C2E38855Q44572496-56672AA0-D2C3-4AE6-8ED8-A7F276D2A38EQ44609308-D01C1AEE-F3BF-4557-8AED-FC53DABBC8CAQ44646663-69968121-8C53-452D-BC57-F495E4BBF720Q44833155-E7DFA76C-19AD-4E53-8FEE-4D66F3D0936FQ44878354-D0D29CAC-B64E-412D-86D3-CE3EFF86ADC5Q44947635-93EE5F8D-E22E-4CBC-B41E-9C19166916B2Q44997047-57F77DBB-8AE6-4955-B435-241C22437F87Q45011430-955F8FF6-5853-4718-AE5A-AE4E09A5AAF7Q45065970-595A3C87-C427-4D1B-85B8-76A02EFF2026Q45180358-B6EB5447-F40E-4224-A466-2DED378F6965Q45930862-51773CC7-AC83-4E26-99AE-B062DD4A4612Q46212849-34B9743E-C961-4CCE-B332-BA9EBD6CCABFQ46313621-D2690CD3-08B2-4021-89DC-DD913A69A168
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Lara Testai
@ast
Lara Testai
@en
Lara Testai
@es
Lara Testai
@nl
type
label
Lara Testai
@ast
Lara Testai
@en
Lara Testai
@es
Lara Testai
@nl
prefLabel
Lara Testai
@ast
Lara Testai
@en
Lara Testai
@es
Lara Testai
@nl
P106
P1153
6602478959
P21
P31
P496
0000-0003-2431-6248